文献速递前列腺增生与排尿功能障碍

骶神经调控一期运动反应电压≤3V与≥4V对女性OAB或尿潴留疗效比较

Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
PubMed 文献 · BJU Int · 2018-05-17

该回顾性双队列研究纳入339例药物难治性OAB或非梗阻性尿潴留女性患者,比较骶神经调控一期运动反应电压≤3V与≥4V的临床结局。结果显示≤3V组二期转化率、成功率更高,电池寿命更长且程控次数更少,但1V患者更易出现程控相关疼痛和足趾跖屈。

要点

  • OAB患者中≤3V组二期转化率93.5%显著高于≥4V组72.3%(P<0.001)。
  • ≤3V组成功率82.1%高于≥4V组63%(P<0.001),电池寿命延长且年程控次数减少。
  • 1V患者32%在程控电压微增时出现严重盆腔/直肠周围疼痛和拇趾跖屈。

核心结论

  • ≤3V组在OAB和尿潴留患者中多数临床排尿参数改善达40%。
  • 电压<2V可能引发自身程控疼痛和严重腹部肌肉收缩及足趾跖屈,或影响患者接受治疗调整。
  • 建议开展随机对照试验确认结果。

研究设计与样本

  • 观察性回顾性双队列研究,纳入339例药物难治性OAB或尿潴留女性患者。
  • OAB组:A组174例运动反应≤3V,B组110例≥4V;尿潴留组:C组33例≤3V,D组22例≥4V。
  • 2001年9月至2014年9月期间均成功完成一期至二期骶神经调控置入。

主要发现

  • A组平均随访116.3(30.3)个月,B组112(34.6)个月(P<0.354);C组150.5(20.4)个月,D组145.8(17.2)个月(P<0.38)。
  • A组二期转化率93.5%(174/186) vs B组72.3%(110/152),P<0.001;C组94%(34/36) vs D组70%(21/30),P<0.017。
  • A组成功率82.1%(143/174) vs B组63%(69/110),P<0.001;成功率定义为频率、尿急、急迫性尿失禁、夜尿及UDI-6和IIQ-7评分下降≥50%。
  • ≤3V两组电池寿命改善(P<0.001),A组和C组年程控次数减少(P<0.001)。
  • 1V患者32%在程控电压微增(0.1-0.2V)时出现严重盆腔/直肠周围疼痛和拇趾跖屈,2V和3V患者分别仅7%和1%(P<0.001)。

关键数值与推荐

  • 运动反应≤3V与≥4V分组比较。
  • 成功定义为频率、尿急、急迫性尿失禁、夜尿及UDI-6和IIQ-7评分下降≥50%。
  • 二期转化率A组93.5%(174/186) vs B组72.3%(110/152)(P<0.001);C组94%(34/36) vs D组70%(21/30)(P<0.017)。
  • 成功率A组82.1%(143/174) vs B组63%(69/110)(P<0.001)。

临床怎么用

  • 骶神经调控一期测试中运动反应电压≤3V与更好的二期转化率和临床成功率相关。
  • 电压<2V时需警惕程控相关疼痛和足趾跖屈运动,可能影响患者治疗调整。
  • ≤3V组电池寿命更长且年程控次数更少。

局限性

  • 回顾性观察性设计,非随机对照。
  • 样本来自单中心,可能存在选择偏倚。
  • 作者建议随机对照试验确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether the utilisation of a motor response of <3 V during Stage 1 sacral neuromodulation (SNM) results in better clinical outcomes compared to >4 V in patients with overactive bladder (OAB) or urinary retention symptoms. PATIENTS AND METHODS: An observational, retrospective, double cohort review was conducted of 339 female patients who had experienced medically recalcitrant OAB or urinary retention symptoms. Between September 2001 and September 2014, both cohorts underwent successful Stage 1 to Stage 2 SNM placement. Group A, included 174 women with a motor response at ≤3 V; and Group B, evaluated 110 women with a motor response at ≥4 V for medically recalcitrant OAB. Group C, compared 33 women with a motor response at ≤3 V; and Group D, documented 22 women with a motor response at ≥4 V for non-obstructive urinary retention. Patients completed 3-day voiding diaries, the Urogenital Distress Inventory-6 (UDI-6), Incontinence Impact Questionnaire-7 (IIQ-7), and Patient Global Impression of Improvement Questionnaire. RESULTS: The mean (sd) follow-up was 116.3 (30.3) months in Group A and 112 (34.6) months in Group B (P < 0.354); 150.5 (20.4) months in Group C and 145.8 (17.2) months in Group D (P < 0.38). Successful conversion of Stage 1 to Stage 2 showed statistically significant improvement for both <3-V groups (Groups A and C). Group A had a 93.5% (174/186) conversion rate vs 72.3% (110/152) in Group B for OAB symptoms (P < 0.001). Group C had a 94% (34/36) conversion rate vs 70% (21/30) in Group D (P < 0.017). Defined as a ≥50% reduction in frequency, urgency, urgency incontinence and nocturia, and UDI-6 and IIQ-7 scores, the success rate for Group A was 82.1% (143/174) and for Group B was 63% (69/110) (P < 0.001). The mean battery life improved in both <3-V cohorts (P < 0.001). Annual reprogramming sessions were reduced in Group A and Group C (P < 0.001). Subset analysis of variance showed no statistical improvement in most patient outcomes when 1-V subjects were compared to 2- and 3-V cohorts. However, 32% of 1-V patients (P < 0.001) noted the onset of severe pelvic/perirectal pain and big toe plantar flexion movement with small increments in voltage (0.1-0.2 V) during reprogramming. Only 7% of 2-V and 1% of 3-V patients experienced this complication. CONCLUSIONS: Significant improvement was noted (up to 40%) in most clinical voiding parameters in the <3-V patients for both OAB and urinary retention. While <3 V will still statistically improve patient outcomes, a voltage <2 V may elicit self-reprogramming pain with severe bellows and plantar flexion movement, which may discourage patients from therapy adjustments. We recommend randomised, controlled trials to confirm these results.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Marinkovic SP, Ford JC. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation. BJU Int. 2018. PMID: 29637712. doi:10.1111/bju.14240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。